Northcoast Research Analysts Raise Earnings Estimates for Zimmer Biomet Holdings Inc (NYSE:ZBH)

Zimmer Biomet Holdings Inc (NYSE:ZBH) – Research analysts at Northcoast Research upped their Q1 2020 EPS estimates for shares of Zimmer Biomet in a report released on Wednesday, November 6th. Northcoast Research analyst D. Keiser now expects that the medical equipment provider will post earnings per share of $1.95 for the quarter, up from their prior forecast of $1.93. Northcoast Research also issued estimates for Zimmer Biomet’s Q2 2020 earnings at $2.07 EPS, Q3 2020 earnings at $1.85 EPS, Q4 2020 earnings at $2.39 EPS and FY2020 earnings at $8.26 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.02. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a negative net margin of 1.14% and a positive return on equity of 13.89%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.63 earnings per share.

ZBH has been the topic of a number of other reports. TheStreet raised shares of Zimmer Biomet from a “c+” rating to a “b” rating in a report on Tuesday. UBS Group boosted their price objective on shares of Zimmer Biomet from $158.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley boosted their price objective on shares of Zimmer Biomet from $143.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Wells Fargo & Co boosted their price objective on shares of Zimmer Biomet from $150.00 to $158.00 and gave the company an “outperform” rating in a report on Monday, September 9th. Finally, Cowen set a $140.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. Zimmer Biomet currently has an average rating of “Buy” and a consensus price target of $147.95.

Shares of ZBH opened at $144.00 on Friday. The firm has a market capitalization of $28.81 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 2.66 and a beta of 1.14. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.19 and a quick ratio of 0.56. Zimmer Biomet has a 1-year low of $96.99 and a 1-year high of $144.96. The company’s fifty day moving average price is $137.06 and its 200-day moving average price is $128.64.

Several institutional investors have recently modified their holdings of ZBH. Personal Wealth Partners acquired a new position in shares of Zimmer Biomet in the second quarter worth about $26,000. TRUE Private Wealth Advisors acquired a new position in shares of Zimmer Biomet in the second quarter worth about $26,000. Allworth Financial LP raised its position in shares of Zimmer Biomet by 65.0% in the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 80 shares during the period. Coastal Investment Advisors Inc. raised its position in shares of Zimmer Biomet by 271.0% in the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 187 shares during the period. Finally, Private Ocean LLC raised its position in shares of Zimmer Biomet by 34.8% in the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 80 shares during the period. Institutional investors and hedge funds own 87.72% of the company’s stock.

In related news, insider Didier Deltort sold 360 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $139.25, for a total transaction of $50,130.00. Following the completion of the transaction, the insider now directly owns 1,194 shares in the company, valued at $166,264.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Chad F. Phipps sold 32,800 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $140.00, for a total transaction of $4,592,000.00. The disclosure for this sale can be found here. Insiders have sold 40,244 shares of company stock valued at $5,621,885 over the last 90 days. 0.72% of the stock is currently owned by insiders.

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.67%. Zimmer Biomet’s dividend payout ratio is presently 12.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: Commodities

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.